R&D Overview

Idenix is developing next-generation oral antiviral therapeutics with a primary focus on hepatitis C virus (HCV) infection. Idenix has drug candidates in two distinct classes of HCV therapies – NS5A inhibitors and nucleotide prodrugs – with the ultimate goal of developing an all-oral pan-genotypic combination regimen.

The target profile for the Idenix HCV product candidates includes oral, once-daily agents with pan-genotypic activity and suitability for fixed-dose combination regimens, as well as high tolerability and low potential for drug-drug interactions.